Z. Sezer Et Al. , "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.," Vaccines , vol.12, no.2, 2024
Sezer, Z. Et Al. 2024. Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.. Vaccines , vol.12, no.2 .
Sezer, Z., Pavel, S. T. I., Inal, A., Yetiskin, H., Kaplan, B., Uygut, M. A., ... Aslan, A. F.(2024). Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.. Vaccines , vol.12, no.2.
Sezer, ZAFER Et Al. "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.," Vaccines , vol.12, no.2, 2024
Sezer, ZAFER Et Al. "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.." Vaccines , vol.12, no.2, 2024
Sezer, Z. Et Al. (2024) . "Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.." Vaccines , vol.12, no.2.
@article{article, author={ZAFER SEZER Et Al. }, title={Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up.}, journal={Vaccines}, year=2024}